Respiratory syncytial virus (RSV) immunisation recommendations This resource summarises the recommendations for receiving RSV vaccine or monoclonal antibody (mAB) according to age group or cohort. Refer to the Australian Immunisation Handbook RSV chapter for detailed recommendations. Last updated: 13 May 2026 Age group or cohort RecommendationProduct name/type (vaccine/mAB)FundingRecommended to receive RSV immunisationPregnant womenA single dose in each pregnancy from 28 weeks gestation Abrysvo (vaccine)Yes; NIP-fundedInfants aged <8 months entering their first RSV seasonA single 50 mg (weight <5 kg) or 100 mg (≥5 kg) dose in infants:who are born within 2 weeks of their mother receiving RSV vaccine who have risk conditions for severe RSV disease, regardless of maternal vaccination who are born to mothers with severe immunosuppression, where the immune response to RSV vaccine was impairedwhose mothers received RSV vaccine in pregnancy but have subsequently undergone a treatment after birth, such as cardiopulmonary bypass or extracorporeal membrane oxygenation, that may lead to loss of maternal antibodies.Nirsevimab (mAB; Beyfortus)Yes; state- and territory-funded, noting funded eligibility may vary from the Australian Immunisation Handbook recommendations. Check state and territory guidelines for details.Infants aged ≥8–24 months entering their second or subsequent RSV seasonA single 200 mg dose, given as two 100 mg injections at the same visit for infants who have a risk condition for severe RSV disease – regardless of maternal vaccination or receipt of nirsevimab in their first RSV season. Adults aged ≥75 yearsA single doseAbrysvo or Arexvy (vaccine)Yes; NIP-funded for Arexvy only from 15 May 2026Aboriginal and Torres Strait Islander adults aged ≥60 yearsA single doseAbrysvo or Arexvy Yes; NIP-funded for Arexvy only from 15 May 2026Adults aged 60–74 years with risk factors for severe RSV diseaseA single doseAbrysvo or Arexvy No*Can consider RSV immunisationAdults aged 50–59 years with risk factors for severe RSV diseaseA single doseArexvyNo*Adults aged 60–74 years A single doseAbrysvo or ArexvyNo* Abbreviations: mAB=monoclonal antibody; NIP=National Immunisation Program; RSV=respiratory syncytial virus* From 15 May 2026, Arexvy will be funded in Western Australia for the following additional groups of older adults:aged 60–74 years who are:living in a residential aged care homereceiving Commonwealth Support at Homeliving in specialist disability accommodation (SDA)in residential mental health servicesexperiencing homelessnessin a correctional facilityaged 50–59 years in one of the above settings and:are Aboriginal and Torres Strait Islanderhave a risk factor for severe RSV disease. Back to respiratory syncytial virus (RSV) immunisation 43 views
